Home » EMA Accepts Genzyme MAA of Multiple Sclerosis Drug
EMA Accepts Genzyme MAA of Multiple Sclerosis Drug
The European Medicines Agency has accepted the Genzyme’s filing of the MAA for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis.
Pharmaceutical Business Review
Pharmaceutical Business Review
Upcoming Events
-
07May
-
14May
-
30May